Results 31 to 40 of about 320 (143)

HYPOLIPIDEMIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN 2004-2010 ACCORDING TO THE PROGNOZ IBS REGISTER

Рациональная фармакотерапия в кардиологии, 2015
Aim. To evaluate the frequency of prescription, efficacy and patients adherence to statin therapy in a cohort of patients with ischemic heart disease (IHD), confirmed by coronary angiography data, during the period from 2004 to 2010 based on the data ...
S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich   +2 more
doaj   +1 more source

TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2)

Рациональная фармакотерапия в кардиологии, 2015
Aim. To assess the quality of drug therapy and its correspondence with current clinical guidelines in patients with proven stable ischemic heart disease (IHD) before admission, during inpatient stay in hospital and after hospital discharge.Material and ...
S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich   +2 more
doaj   +1 more source

THE SAFETY OF STATINS: WHAT A PHYSICIAN NEEDS TO KNOW

Рациональная фармакотерапия в кардиологии, 2015
Various aspects of the safety of statins in clinical practice are discussed: hepatotoxicity, myopathy and rhabdomyolysis, the impact on the diabetes and cognitive dysfunction onset, renal function impairment.
D. A. Napalkov
doaj   +1 more source

MEDICAL SUPERVISION IN SPECIALIZED CENTER AND THE QUALITY OF LIPID-LOWERING THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASES (ACCORDING TO THE PROFIL REGISTER)

Рациональная фармакотерапия в кардиологии, 2015
Aim. To assess the quality of lipid-lowering therapy in high risk patients with cardiovascular diseases during medical supervision in specialized center.Material and methods. The data of the PROFIL register are used.
S. Yu. Martsevich, O. V. Gaysenok, S. G. Tripkosh, A. V. Zagrebelnyy, Yu. V. Lukina   +4 more
doaj   +1 more source

Novaya vekha v ispol'zovani statinov dlya profilaktiki i lecheniya serdechno-sosudistykh oslozhneniy (Po rezul'tatam Heart Protection Study ? HPS)

Сахарный диабет, 2003
До настоящего времени исследования по коррекции дислипопротеинемий статинами включали небольшое количество больных и проводились в рамках вторичной профилактики ИБС у больных с установленной ИБС.
L Chugunova, M Shamkhalova, M Shestakova
doaj   +1 more source

Preimushchestva vklyucheniya v terapiyu bol'nykh s metabolicheskim sindromom i arterial'noy gipertenziey statinov: dopolnitel'nye vozmozhnosti organoprotektsii

Сахарный диабет, 2007
Цель. Изучение возможностей органопротекции при включении Кардиостатина? в терапию больных с МС и АГ. Материалы и методы. В открытое проспективное сравнительное исследование включено 43 пациента в возрасте от 45 до 65 лет с МС и АГ I и II степени тяжести.
M E Statsenko, M M Zemlyanskaya
doaj   +1 more source

Сholesterol lowering therapy and low density lipoprotein peroxidation during atherosclerosis [PDF]

, 2018
атеросклероз, статины, липопротеины низкой ...
Tikhaze, A. K., Lankin, V. Z.
core  

Advantages of combination drug therapy in correction of dyslipidemia in metabolic syndrome and type 2 diabetes mellitus

, 2008
Показана необходимость комбинированной терапии статины/фибраты для контроля нарушений липидного обмена при метаболическом синдроме и диабете.The necessity of combined therapy with statins/fibrates for control of lipid metabolism disorders at metabolic ...
Ковалева, О.Н., Кравченко, Н.А.   +1 more
core   +2 more sources

OSOBENNOSTI VTORIChNOY PROFILAKTIKI IShEMIChESKOY BOLEZNI SERDTsA NA STATsIONARNOM I AMBULATORNOM ETAPAKh

КардиоСоматика, 2011
Вторичная профилактика после перенесенного острого инфаркта миокарда (ОИМ), как известно, включает в себя как модификацию образа жизни, так и медикаментозную терапию.
S. A. Oldueva, I. A. Leonova, N. A. Trostyanetskaya, E. G. Bykova, N. S. Tret'yakova   +4 more
doaj  

MYOPATHY AS A SIDE EFFECT OF STATIN THERAPY: MECHANISMS OF DEVELOPMENT AND PROSPECTS FOR TREATMENT

Рациональная фармакотерапия в кардиологии, 2015
Statins are lipid-lowering drugs with proven efficacy that reduce cardiovascular risk and are well tolerated by most patients. Myopathy as a side effect of statin therapy is one of the most common reasons for their withdrawal. Its severity can range from
O. M. Drapkina, E. M. Chernova
doaj   +1 more source